The CD19-expressing tumor cells, including Nalm-6 (acute lymphoblastic leukemia tumor cell line), Raji (Burkitt’s lymphoma tumor cell line), and primary tumor cells from CD19-positive human B cell lymphoma and leukemia, were selected as targets for cytotoxicity assay. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.